New prostate cancer biomarkers move closer to clinical use

June 17, 2011

Conway Fellow, Professor William Watson and Professor John Fitzpatrick, UCD School of Medicine and Medical Science and Mater Misericordiae University Hospital recently received a translational research award for the validation of a panel of serum biomarkers to inform surgical intervention for prostate cancer.

One of four research projects to be funded under the joint Health Research Board and Science Foundation Ireland initiative, this proposal ultimately aims to develop a clinically-applicable predictive tool to identify the grade and stage of prostate cancer and inform the clinician and patient of the most appropriate .

The proposal is based on recently published and preliminary data by the UCD prostate cancer group and will involve independent external validation of the panel of proteins by international collaborators in Austria and Australia prior to any commercial development taking place.

Dr Sheng-Fei Oon (MD research student) published reviews in Nature Reviews Urology and the BJU International that systematically identified, for the first time, all the areas of greatest unmet need for biomarkers in prostate cancer and has directed the focus of international biomarker research efforts to these areas maximising clinical utility.

Taking this as a guide, Mr Yue Fan (PhD student on the UCD Bioinformatics and PhD programme) used a proteomics approach and novel bioinformatics analysis to identify lists of potential candidate . These findings, published in the , will help stratify prostate cancer patients into their appropriate treatment groups.

“There are many hundreds of biomarkers for prostate cancer but only one in clinical use because the others have either not succeeded in the validation phase or were not deemed useful at the bedside” stated Professor William Watson who leads the group and the Irish Prostate Cancer Research Consortium.

“We have taken the approach of firstly identifying the relevant clinical questions and then designing appropriate discovery and validation efforts with a clearly defined comparison population using carefully calibrated and standardised collection, storage and processing protocols.”

This multi-faceted, but unified approach is placing Irish-based prostate cancer research in the forefront of many international research interests.

More information: References:

Fan Y, Murphy TB, Byrne JC, Brennan L, Fitzpatrick JM, Watson RW. Applying random forests to identify biomarker panels in serum 2D-DIGE data for the detection and staging of prostate cancer. J Proteome Res. 2011 Mar 4;10(3):1361-73.

Oon SF, Pennington SR, Fitzpatrick JM, Watson RW. Biomarker research in prostate cancer-towards utility, not futility. Nat Rev Urol. 2011 Mar;8(3):131-8.

Oon SF, Watson RW, O’Leary JJ, Fitzpatrick JM. Epstein Criteria for prostate cancer. BJU Int. 2011 Feb 14. doi: 10.1111/j.1464-410X.2011.09979.x. [Epub ahead of print]

Related Stories

Recommended for you

Vitamin C may encourage blood cancer stem cells to die

August 17, 2017
Vitamin C may "tell" faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers. This is the finding of a study led by researchers from Perlmutter Cancer Center at NYU Langone ...

Outdoor light at night linked with increased breast cancer risk in women

August 17, 2017
Women who live in areas with higher levels of outdoor light at night may be at higher risk for breast cancer than those living in areas with lower levels, according to a large long-term study from Harvard T.H. Chan School ...

Scientists develop novel immunotherapy technology for prostate cancer

August 17, 2017
A study led by scientists at The Wistar Institute describes a novel immunotherapeutic strategy for the treatment of cancer based on the use of synthetic DNA to directly encode protective antibodies against a cancer specific ...

Scientists develop blood test that spots tumor-derived DNA in people with early-stage cancers

August 16, 2017
In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center report they have developed a test that spots tiny amounts of cancer-specific DNA in blood and have used it to ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.